mRNA‐Lipid Nanoparticle‐Mediated Restoration of PTPN14 Exhibits Antitumor Effects by Overcoming Anoikis Resistance in Triple‐Negative Breast Cancer
Advanced Science · 2024
DOI: 10.1002/advs.202309988 ↗Kurz gefasst
Fachartikel in der Zeitschrift Advanced Science, 2024. Verfasst von Wei Li und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Pharmacology, Hunan Key Laboratory of Pharmacogenetics, and National Clinical Research Center for Geriatric Disorders, Xiangya…. Hauptthemen laut MEDLINE: Triple Negative Breast Neoplasms, Anoikis, Nanoparticles, Protein Tyrosine Phosphatases, Non-Receptor. Die Arbeit wurde bisher 16-mal zitiert (Crossref) und nennt 54 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China, Technology Innovation Action Plan, Medical-Industrial Intersection.
Abstract (Originalsprache)
Triple‐negative breast cancer (TNBC) poses a challenging prognosis due to early metastasis driven by anoikis resistance. Identifying crucial regulators to overcome this resistance is vital for improving patient outcomes. In this study, a genome‐wide CRISPR/Cas9 knockout screen in TNBC cells has identified tyrosine‐protein phosphatase nonreceptor type 14 (PTPN14) as a key regulator of anoikis resistance. PTPN14 expression has shown a progressive decrease from normal breast tissue to metastatic tumors. Overexpressing PTPN14 has induced anoikis and inhibited cell proliferation in TNBC cells, while normal human breast cells are unaffected. Mechanistically, PTPN14 is identified as a key factor in dephosphorylating breast cancer antiestrogen resistance 3, a novel substrate, leading to the subsequent inhibition of PI3K/AKT and ERK signaling pathways. Local delivery of in vitro transcribed PTPN14 mRNA encapsulated by lipid nanoparticles in a TNBC mouse model has effectively inhibited tumor growth and metastasis, prolonging survival. The study underscores PTPN14 as a potential therapeutic target for metastatic TNBC, with the therapeutic strategy based on mRNA expression of PTPN14 demonstrating clinical application prospects in alleviating the burden of both primary tumors and metastatic disease.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Clinical Pharmacology, Hunan Key Laboratory of Pharmacogenetics, and National Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Central South University, Changsha, 410008, P. R. China.
- Institute of Clinical Pharmacology, Engineering Research Center for applied Technology of Pharmacogenomics of Ministry of Education, Central South University, Changsha, 410078, P. R. China.
- Department of Biochemistry and Molecular Cell Biology, Shanghai Key Laboratory for Tumor Microenvironment and Inflammation, Shanghai Jiao Tong University School of Medicine, Shanghai, 200025, P. R. China.
- Department of Neurosurgery, Xiangya Hospital, Central South University, Changsha, 410008, P. R. China.
- Department of Gastrointestinal Surgery, Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, 200127, P. R. China.
- Department of Nephrology, Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, 200127, P. R. China.
ORCID-Profile: Zhaoqian Liu
Förderung
- National Natural Science Foundation of China
- Technology Innovation Action Plan
- Medical-Industrial Intersection
- Key Research and Development Program of Hunan Province of China
- Natural Science Foundation of Hunan Province
Zitieren
APA
Li, W., Huang, M., Wu, Z., Zhang, Y., Cai, Y., Su, J., Xia, J., Yang, F., Xiao, D., Yang, W., Xu, Y., & Liu, Z. (2024). mRNA‐Lipid Nanoparticle‐Mediated Restoration of PTPN14 Exhibits Antitumor Effects by Overcoming Anoikis Resistance in Triple‐Negative Breast Cancer. Advanced Science. https://doi.org/10.1002/advs.202309988
Vancouver
Li W, Huang M, Wu Z, Zhang Y, Cai Y, Su J, et al. mRNA‐Lipid Nanoparticle‐Mediated Restoration of PTPN14 Exhibits Antitumor Effects by Overcoming Anoikis Resistance in Triple‐Negative Breast Cancer. Advanced Science. 2024. doi:10.1002/advs.202309988
BibTeX
@article{Li2024,
author = {Li, Wei and Huang, Masha and Wu, Zhaoping and Zhang, Yu and Cai, Ying and Su, Juncheng and Xia, Jia and Yang, Fan and Xiao, Desheng and Yang, Wen and Xu, Yingjie and Liu, Zhaoqian},
title = {mRNA‐Lipid Nanoparticle‐Mediated Restoration of PTPN14 Exhibits Antitumor Effects by Overcoming Anoikis Resistance in Triple‐Negative Breast Cancer},
journal = {Advanced Science},
year = {2024},
doi = {10.1002/advs.202309988}
}
EUVIMED